Somatostatin Expressing (Som) Cortical Interneurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Somatostatin-expressing (SOM) interneurons are a major class of cortical GABAergic neurons that target dendritic shafts of pyramidal cells, providing feedforward and feedback inhibition[1]. They are critical for regulating cortical excitability and are significantly affected in neurodegenerative diseases[2]. [2:1]
Somatostatin Cortical Interneurons are specialized neurons in the brain that play important roles in neurological function and are relevant to neurodegenerative diseases. These neurons are involved in critical processes such as neurotransmitter regulation, autonomic control, or sensory processing. [3]
Dysfunction or degeneration of these neurons contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders through effects on neurotransmitter systems, cellular metabolism, or neural circuit function. [4]
--- [5]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4023017 | sst GABAergic interneuron |
SOM interneurons are found throughout all layers of the cerebral cortex, with highest density in layers 2-4[3:1]. Their axons primarily target the dendritic shafts of pyramidal cells, making them distinct from basket cells that target somata[4:1]. [6]
The defining feature is expression of somatostatin-14 and somatostatin-28, neuropeptides that inhibit neurotransmitter release[1:1]. [7]
Many SOM cells co-express neuropeptide Y[5:1]. [8]
A subset expresses calbindin D-28k[3:2]. [9]
The most common SOM subtype, with ascending axonal projections to layer 1 targeting pyramidal cell dendrites[7:1]. [10]
Found in deeper layers with different axonal targeting patterns[8:1]. [11]
The study of Somatostatin Expressing (Som) Cortical Interneurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [12:1]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [13:1]
Additional evidence sources: [14:1] [15:1] [16:1] [17:2]
Jin CY, et al. (1992). Journal of Comparative Neurology. 1992. ↩︎ ↩︎
Palop JJ, Mucke L (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nature Neuroscience. 2010. ↩︎ ↩︎ ↩︎
Rudy B, et al. (2011). Trends in Neurosciences. 2011. ↩︎ ↩︎ ↩︎ ↩︎
Klausberger T, Somogyi P (2008). Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science. 2008. ↩︎ ↩︎ ↩︎ ↩︎
Kubota Y, et al. (2011). Journal of Neuroscience. 2011. ↩︎ ↩︎
Kubota Y, et al. [(1994)](https://doi.org/10.1016/0006-8993(94). Brain Research. 1994. ↩︎ ↩︎
Wang Y, et al. (2004). Journal of Physiology. 2004. ↩︎ ↩︎ ↩︎
Silberberg G, Markram H (2007). Disynaptic inhibition between neocortical pyramidal cells mediated by Martinotti cells. Neuron. 2007. ↩︎ ↩︎
Davies P, et al. [(1980)](https://doi.org/10.1016/0006-8993(80). Brain Research. 1980. ↩︎ ↩︎
[Davies P, Terry RD (1981). Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia](https://doi.org/10.1016/0197-4580(81). Neurobiology of Aging. 1981. ↩︎ ↩︎
Braak H, et al. [(2003)](https://doi.org/10.1016/S0197-4580(02). Neurobiology of Aging. 2003. ↩︎ ↩︎
Cepeda C, et al. (2013). Current Opinion in Neurobiology. 2013. ↩︎ ↩︎ ↩︎